Skip to main navigation Skip to search Skip to main content

Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients

  • Ravi Vij
  • , Jonathan L. Kaufman
  • , Andrzej J Jakubowiak
  • , A. Keith Stewart
  • , Sundar Jagannath
  • , Vishal Kukreti
  • , Kevin T. McDonagh
  • , Melissa Alsina
  • , Nizar J Bahlis
  • , Andrew Belch
  • , Frederic J. Reu
  • , Nashat Y Gabrail
  • , Jeffrey Matous
  • , David H. Vesole
  • , Robert Z. Orlowski
  • , Mai H. Le
  • , Peter Lee
  • , Michael Wang
  • Washington University in St. Louis
  • Emory University
  • University of Michigan
  • Mayo Clinic
  • Mount Sinai Hospital
  • Div. of Hematology/Oncology, Princess Margaret Hospital, Toronto, ON, Canada,
  • University of Kentucky
  • Blood and Marrow Transplant, H. Lee Moffitt Cancer Center, Tampa, FL, USA,
  • University of Calgary
  • University of Alberta
  • Taussig Cancer Center, Cleveland, OH, USA,
  • Gabrail Cancer Center Research, Canton, USA,
  • Rocky Mountain Cancer Ctr., Denver, CO, USA,
  • Hackensack University Medical Center
  • University of Texas MD Anderson Cancer Center
  • Onyx Pharmaceuticals
  • Tower Cancer Research Foundation

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
JournalBlood
Volume116
Issue number21
DOIs
StatePublished - Nov 19 2010
Externally publishedYes

Disciplines

  • Immunology and Infectious Disease
  • Medicine and Health Sciences
  • Internal Medicine

Cite this